M&A and equity raisings
6,065 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
US deals dated after 30 September 2026 are still being collected.
73 deals · US$14bndisclosed · Biotech · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Apr 2026 | Kailera Therapeutics | – | – | IPO | Announced | 625.0 | Biotech+1 | Latham & Watkins (issuer)William Blair (lead manager)J.P. Morgan (lead manager)Jefferies (lead manager)Leerink Partners (lead manager)TD Securities (lead manager)Evercore (lead manager)Paul Hastings (lead manager) |
| Apr 2026 | Obsidian Therapeutics | – | – | Placement | Completed | 350.0 | Biotech+2 | GoodwinSidley Austin (issuer)Leerink Partners (lead manager)TD Securities (lead manager)Piper Sandler (lead manager)William Blair (lead manager)LifeSci Capital (lead manager)Mintz (lead manager) |
| Apr 2026 | Korsana Biosciences | – | – | Placement | Announced | 380.0 | Biotech+1 | Cooley (lead manager) |
| Mar 2026 | Pulmatrix | – | – | Placement | Announced | 19.0 | Biotech | Palladium Capital Group (lead manager) |
| Mar 2026 | Imugene | – | – | Placement | Completed | 14.0 | Biotech+1 | McCullough Robertson (issuer)E&P Capital (lead manager)Barrenjoey (lead manager)Bell Potter (lead manager) |
| Mar 2026 | Candid Therapeutics | – | – | Placement | Pending | 505.0 | Biotech+1 | Cooley (issuer)Jefferies (lead manager)BofA Securities (lead manager)TD Securities (lead manager)Cantor Fitzgerald (lead manager)Latham & Watkins (lead manager) |
| Feb 2026 | Generate Biomedicines | – | – | IPO | Listed | 400.0 | Biotech+2 | Goodwin (issuer)Goldman Sachs (lead manager)Morgan Stanley (lead manager)Piper Sandler (lead manager)Guggenheim Securities (lead manager)Cantor Fitzgerald (lead manager)Latham & Watkins (lead manager) |
| Feb 2026 | Sensei Biotherapeutics | – | – | Placement | Pending | 200.0 | Biotech+2 | Cantor Fitzgerald (issuer)Citi (issuer)Sidley Austin (issuer)Leerink Partners (lead manager) |
| Feb 2026 | Liminatus Pharma | – | – | Follow-on offering | Announced | 4.0 | Biotech+2 | Loeb & Loeb (issuer)Maxim Group (lead manager)Lucosky Brookman (lead manager) |
| Feb 2026 | Agomab Therapeutics NV | – | – | IPO | Announced | 200.0 | Biotech+2 | Goodwin (issuer)Baker McKenzie (issuer)J.P. Morgan (lead manager)Morgan Stanley (lead manager)Leerink Partners (lead manager)Van Lanschot Kempen (lead manager)Davis Polk (lead manager)Clifford Chance (lead manager) |
| Feb 2026 | Eikon Therapeutics | – | – | IPO | Announced | 381.2 | Oncology+1 | Covington & Burling (issuer)J.P. Morgan (lead manager)Morgan Stanley (lead manager)BofA Securities (lead manager)Cantor Fitzgerald (lead manager)Mizuho Securities (lead manager)Davis Polk (lead manager) |
| Feb 2026 | Veradermics | – | – | IPO | Announced | 256.3 | Dermatology+2 | Ropes & Gray (issuer)Jefferies (lead manager)Leerink Partners (lead manager)Citi (lead manager)Cantor Fitzgerald (lead manager)Cooley (lead manager) |
| Feb 2026 | Perspective Therapeutics | – | – | Follow-on offering | Announced | 175.0 | Radiopharmaceuticals+2 | Piper Sandler (lead manager)UBS (lead manager)Oppenheimer & Co. (lead manager)Truist Securities (lead manager)LifeSci Capital (lead manager) |
| Jan 2026 | Polaryx Therapeutics | – | – | Direct listing | Completed | – | Biotech+1 | Maxim Group (issuer)Gibson Dunn (issuer)Brownstein Hyatt Farber Schreck (issuer) |
| Jan 2026 | AdAlta | – | – | Placement | Completed | 0.8 | Biotech+1 | Sixty Two Capital (lead manager) |
| Jan 2026 | Aktis Oncology | – | – | IPO | Listed | 317.7 | Biotech+2 | Paul Hastings (issuer)Goodwin (issuer)J.P. Morgan (lead manager)BofA Securities (lead manager)Leerink Partners (lead manager)TD Securities (lead manager)Davis Polk (lead manager) |
| Jan 2026 | Suzhou Ribo Life Science Co. | – | – | IPO | Listed | – | Biotech+2 | Kirkland & Ellis (issuer)CICC (lead manager)Citi (lead manager) |
| Dec 2025 | Apimeds Pharmaceuticals US | – | – | Convertible | Completed | 10.9 | Pharma+1 | Nelson Mullins Riley & Scarborough (issuer)EF Hutton (lead manager) |
| Sep 2025 | Neurizon Therapeutics | – | – | Placement | Completed | 3.3 | Biotech+1 | Petra Capital (lead manager) |
| May 2025 | Chimeric Therapeutics | – | – | Placement | Announced | 4.2 | Biotech+2 | PAC Partners (lead manager)Taylor Collison (lead manager) |
| – | Lakewood-Amedex Biotherapeutics | – | – | Direct listing | Announced | – | Biotech+1 | RBW Capital Partners (issuer) |
| – | Silexion Therapeutics Corp | – | – | Follow-on offering | Announced | 2.5 | Biotech+2 | Conyers (issuer)Greenberg Traurig (issuer)H.C. Wainwright & Co. (lead manager)Ellenoff Grossman & Schole (lead manager) |
| – | Vogenx | – | – | IPO | Announced | 81.3 | Biotech | Smith Anderson (issuer)JonesTrading (lead manager)Sichenzia Ross Ference Carmel (lead manager) |
Deals come from stock exchange announcements and filings, takeover and scheme documents, prospectuses, the advisers' own deal announcements and the press. How the data is built All countries counts every deal, wherever it is, including deals whose geography is not known.Country pages cover Australia, New Zealand and the United States. The United Kingdom, Canada, Singapore, China and India are planned.